Samsung Biologics Recognized for Advancing Sustainability

Wins Sustainability Leadership Award at 2026 CDMO Leadership Awards

Mar. 27, 2026 at 2:54am

Got story updates? Submit your updates here. ›

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), was recognized at the 2026 CDMO Leadership Awards for its efforts to advance sustainable practices across its operations and value chain. The company received the Sustainability Leadership Award, a jury-selected distinction, and was also named "Best in Class" in Cultural Fit in the 'Biologics—Large CDMOs' category.

Why it matters

As a major player in the CDMO industry, Samsung Biologics' commitment to sustainability sets an important example for the biopharmaceutical sector. The company's focus on integrating sustainable practices throughout its business and partnerships aligns with growing industry and consumer demands for more environmentally responsible operations.

The details

Samsung Biologics was recognized for its long-term efforts to embed sustainability across its operations and partnerships. This includes implementing a product carbon footprint (PCF) system, achieving a Platinum rating from EcoVadis for its sustainability practices, and serving as a Champion of the Sustainable Markets Initiative (SMI) Health Systems Task Force. The company also plans to further strengthen engagement with global suppliers on decarbonization and building more resilient value chains.

  • The 2026 CDMO Leadership Awards ceremony took place in New York on the sidelines of DCAT Week.

The players

Samsung Biologics

A leading contract development and manufacturing organization (CDMO) that offers end-to-end integrated services ranging from late discovery to commercial manufacturing.

John Rim

President and CEO of Samsung Biologics, who also serves as champion for the Sustainable Markets Initiative (SMI) Supply Chains Working Group.

Got photos? Submit your photos here. ›

What they’re saying

“Sustainability is a core value at Samsung Biologics and guides how we pursue excellence throughout our business and partnerships. This recognition reflects the trust our clients and partners continue to place in us, as well as the dedication of our teams who consistently strive to integrate sustainable practices across our operations. We will continue to advance these efforts in close collaboration with our partners, supporting their long-term goals and the delivery of high-quality, life-saving medicines to patients worldwide.”

— John Rim, President and CEO of Samsung Biologics

What’s next

Samsung Biologics plans to further strengthen its engagement with global suppliers in decarbonization efforts and the development of more resilient value chains.

The takeaway

Samsung Biologics' recognition for its sustainability leadership demonstrates the biopharmaceutical industry's growing focus on integrating environmentally responsible practices throughout its operations and supply chains. As a major CDMO, the company's commitment to sustainability sets an important example for the sector.